Braveheart Bio (NASDAQ:BRVE) Trading Up 8% – What’s Next?

Braveheart Bio, Inc. (NASDAQ:BRVE) shares traded up 8% on Tuesday . The stock traded as high as $28.13 and last traded at $28.87. 36,977 shares changed hands during trading, a decline of 89% from the average daily volume of 342,337 shares. The stock had previously closed at $26.74.

Analyst Upgrades and Downgrades

A number of analysts have commented on BRVE shares. Zacks Research upgraded Braveheart Bio to a “hold” rating in a research report on Tuesday, September 1st. Jefferies Financial Group assumed coverage on Braveheart Bio in a research note on Monday, August 31st. They set a “buy” rating and a $48.00 price target on the stock. Stifel Nicolaus assumed coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They set a “buy” rating and a $45.00 price objective for the company. TD Cowen started coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating on the stock. Finally, The Goldman Sachs Group began coverage on Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating and a $48.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

Braveheart Bio Stock Performance

Braveheart Bio (NASDAQ:BRVE) last announced its quarterly earnings data on Tuesday, September 8th. The company reported ($2.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($2.26). Sell-side analysts anticipate that Braveheart Bio, Inc. will post -0.98 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Erez Chimovits bought 1,940,000 shares of Braveheart Bio stock in a transaction on Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the purchase, the director directly owned 11,901,826 shares of the company’s stock, valued at approximately $214,232,868. This trade represents a 19.47% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Growth Opportunities F. Forbion purchased 1,680,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $30,240,000.00. Following the acquisition, the insider owned 10,185,478 shares of the company’s stock, valued at approximately $183,338,604. The trade was a 19.75% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have acquired 8,751,942 shares of company stock worth $157,534,956.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.